Publications (3)0.72 Total impact
-
Article: [Change of antimalarial first-line treatment in Burkina Faso in 2005].
[show abstract] [hide abstract]
ABSTRACT: Burkina Faso has recently changed the antimalarial drug policy to artesunate/amodiaquine or artemether/lumefantrine as the first-line antimalarial drug and sulfadoxine/pyrimethamine for the intermittent preventive treatment in pregnant woman. Before the implementation of this new strategy we conducted an in vivo efficacy study with chloroquine or sulfadoxine/pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in urban area of Burkina from September to December 2003. Chloroquine (25 mg/kg over 3 days) or sulfadoxine/pyrimethamine (25 mg/kg + 0.025 mg/kg single dose) was administered respectively to 137 and 125 children aged from 6 to 59 months old in a randomized, opened study. Follow up extended over 28 days using modified WHO protocol. After adjusting the results by PCR, treatment failures rates were 63.4% (83/131) and 13.8% (17/123) respectively for chloroquine and sulfadoxine/pyrimethamine. These results with other observations have justified the change of malaria therapy policy in Burkina Faso in 2005.Bulletin de la Société de pathologie exotique 03/2009; 102(1):31-5. -
Article: [Comparative impact of three malaria preventive regimens during pregnancy on maternal anemia due to malaria in Burkina Faso].
[show abstract] [hide abstract]
ABSTRACT: The main objective of this study was to compare the efficacy of three regimens of malaria prevention during pregnancy for the reduction of anemia between the first and third antenatal consultations. The first treatment arm was the classical weekly chemoprophylaxis with chloroquine; the other two were the intermittent preventive treatment using either three doses of chloroquine or sulfadoxine-pyrimethamine. We conducted an open, randomized, three-arm study in a rural district of Burkina Faso. A cohort was constituted by 648 pregnant women of any parity. The hemoglobin gain was more significant with the intermittent preventive treatment using sulfadoxine-pyrimethamine compared to the other treatment arms. The hemoglobin increased from 10.3g/dl (at the first antenatal consultation) to 11.4 g/dl (at the third antenatal consultation). In the three arms of treatment, the chemoprophylaxis reduced the prevalence of moderate anemia and severe anemia. The reduction of moderate anemia was more substantial in the sulfadoxine-pyrimethamine arm (65.6 to 36.7%) at second antenatal consultation (p=0.069) and third antenatal consultation (p=0.014). Conversely, in the two chloroquine arms, there was no significant reduction either at second antenatal consultation (p=0.72) or third antenatal consultation (p=0.55). The prevalence of peripheral parasitemia decreased in all treatment groups. However, it was significantly higher in the sulfadoxine-pyrimethamine group (44.3%). Intermittent preventive treatment with three doses of sulfadoxine-pyrimethamine is a more effective strategy to prevent maternal anemia during pregnancy in Burkina Faso.Médecine et Maladies Infectieuses 05/2008; 38(4):180-6. · 0.72 Impact Factor -
Article: Impact comparatif de trois schémas de prévention du paludisme pendant la grossesse sur l’anémie maternelle, associée à l’infection palustre au Burkina Faso
[show abstract] [hide abstract]
ABSTRACT: Objectives The main objective of this study was to compare the efficacy of three regimens of malaria prevention during pregnancy for the reduction of anemia between the first and third antenatal consultations. The first treatment arm was the classical weekly chemoprophylaxis with chloroquine; the other two were the intermittent preventive treatment using either three doses of chloroquine or sulfadoxine–pyrimethamine.DesignWe conducted an open, randomized, three-arm study in a rural district of Burkina Faso. A cohort was constituted by 648 pregnant women of any parity.ResultsThe hemoglobin gain was more significant with the intermittent preventive treatment using sulfadoxine–pyrimethamine compared to the other treatment arms. The hemoglobin increased from 10.3 g/dl (at the first antenatal consultation) to 11.4 g/dl (at the third antenatal consultation). In the three arms of treatment, the chemoprophylaxis reduced the prevalence of moderate anemia and severe anemia. The reduction of moderate anemia was more substantial in the sulfadoxine–pyrimethamine arm (65.6 to 36.7%) at second antenatal consultation (p = 0.069) and third antenatal consultation (p = 0.014). Conversely, in the two chloroquine arms, there was no significant reduction either at second antenatal consultation (p = 0.72) or third antenatal consultation (p = 0.55). The prevalence of peripheral parasitemia decreased in all treatment groups. However, it was significantly higher in the sulfadoxine–pyrimethamine group (44.3%).Conclusions Intermittent preventive treatment with three doses of sulfadoxine–pyrimethamine is a more effective strategy to prevent maternal anemia during pregnancy in Burkina Faso.Médecine et Maladies Infectieuses. 38(4):180-186.
